Menu Search
Equities

BridgeBio Pharma Inc

BBIO:NSQ

BridgeBio Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.96
  • Today's Change-0.77 / -2.88%
  • Shares traded1.66m
  • 1 Year change-9.04%
  • Beta1.0863
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year BridgeBio Pharma Inc's revenues fell -88.02% from 77.65m to 9.30m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 481.18m to a larger loss of 643.20m.
Gross margin98.91%
Net profit margin-210.62%
Operating margin-187.38%
Return on assets-71.11%
Return on equity--
Return on investment-89.59%
More ▼

Cash flow in USDView more

In 2023, cash reserves at BridgeBio Pharma Inc fell by 22.15m. Cash Flow from Financing totalled 451.54m or 4,853.65% of revenues. In addition the company used 527.72m for operations while cash from investing totalled 54.03m.
Cash flow per share-2.59
Price/Cash flow per share--
Book value per share-5.81
Tangible book value per share-5.95
More ▼

Balance sheet in USDView more

BridgeBio Pharma Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. BridgeBio Pharma Inc has considerable financial risk.
Current ratio4.59
Quick ratio--
Total debt/total equity--
Total debt/total capital2.70
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.